Molecular Imaging To Advance Treatment Of Dementia
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Molecular imaging using a scan technique called positron emission tomography, enables detection and measurement of specific pathological features of disease such as the amyloid plaques of Alzheimer’s disease. This project will develop this technology for other aspects of brain disorders including dementias, Parkinson’s disease, traumatic brain injury and schizophrenia and use it to assist development of therapies and improve clinical diagnosis nation wide.
Molecular Imaging Of Cancers With Copper And Zirconium Radiopharmaceuticals
Funder
National Health and Medical Research Council
Funding Amount
$466,475.00
Summary
This research aims to develop new imaging agents to assist in the diagnosis of breast cancer. This research will advance knowledge in the areas of chemistry, biotechnology and diagnostic imaging.
The Development Of Innovative Multiplexed Molecular Imaging Technology Targeting Improved Diagnostic Imaging Of Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$403,599.00
Summary
Glioblastoma Multiforme (GBM) is extremely invasive and the most lethal of all primary brain tumours. To optimise treatment planning, we propose to develop novel Multiplexed Molecular Imaging (MMI) technology employing the latest PET-MRI hybrid imaging technology. Our strategy targets the development of new F19 MRI MI agents for measuring tumour infiltration that can be multiplexed with F18 PET hypoxia tracers. Our MI agents can also act as conjugative vehicles for drug delivery.
Optimizing Lung Cancer Diagnostic And Staging Pathways Through The Innovative Use Of Thoracic Imaging
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
This research aims to simplify the initial work-up for lung cancer diagnosis. Currently most patients undergo complex investigations and multiple biopsies. Common imaging technology e.g. ultrasound, PET and CT scans may help choose the best and least invasive biopsy procedure. My research will explore this through three complementary studies. If positive, >10000 Australians with lung cancer will benefit each year, and the majority of them will only have to undergo one biopsy procedure.
Novel 18F And 64Cu Labelled Targeted Nanoparticles For Molecular Positron Emission Tomography: A Means For Early And Sensitive Detection Of Thrombosis, Inflammation And Vulnerable, Rupture-prone Atherosclerotic Plaques
Funder
National Health and Medical Research Council
Funding Amount
$572,931.00
Summary
The aim of this project is to develop novel targeted positron emission tomography imaging agents that seek out specific markers for various states of cardiovascular disease. These agents would provide a method for detecting the presence and level of atherosclerosis and thrombotic events. The targeted nanoparticles may provide a unique opportunity to detect very early plaques and the vulnerability of existing plaques.
This Fellowship will focus on the development of novel therapeutics for cancer, and identify mechanisms for selection of treatments best suited to individual patients. It will also develop innovative strategies to identify cancer through molecular imaging techniques.
Investigating Neuroinflammation And Its Relationship With Progressive Brain Structural Loss In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$466,252.00
Summary
This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using novel brain scanning we will index whether brain cells involved in inflammation, called microglia, are in an activated state in people with schizophrenia. We expect microglia will be ‘activated’ in a subgroup of patients with schizophrenia, and will be related to progressive brain volume loss in these patients. This information will help us develop new treatme ....This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using novel brain scanning we will index whether brain cells involved in inflammation, called microglia, are in an activated state in people with schizophrenia. We expect microglia will be ‘activated’ in a subgroup of patients with schizophrenia, and will be related to progressive brain volume loss in these patients. This information will help us develop new treatments to prevent brain volume loss in the illness.Read moreRead less
Novel Radioligands For PET Imaging And Phenotyping Of Multiple Sclerosis Diagnosis
Funder
National Health and Medical Research Council
Funding Amount
$817,828.00
Summary
This project aims to catalyse a paradigm shift in the management of multiple sclerosis (MS). We will achieve this paradigm shift by developing radioligands that can be used to image the brain of MS patients. These agents will target a protein in MS patients that will be diagnostic of the state of disease progression. This will facilitate prediction of disease outcome, monitoring of therapeutic response and the development of novel treatment strategies for the better treatment of MS.